Cargando…

Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood

Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to q...

Descripción completa

Detalles Bibliográficos
Autores principales: Decaris, Martin L., Li, Kelvin W., Emson, Claire L., Gatmaitan, Michelle, Liu, Shanshan, Wang, Yenny, Nyangau, Edna, Colangelo, Marc, Angel, Thomas E., Beysen, Carine, Cui, Jeffrey, Hernandez, Carolyn, Lazaro, Len, Brenner, David A., Turner, Scott M., Hellerstein, Marc K., Loomba, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516243/
https://www.ncbi.nlm.nih.gov/pubmed/27706836
http://dx.doi.org/10.1002/hep.28860
_version_ 1783251129708052480
author Decaris, Martin L.
Li, Kelvin W.
Emson, Claire L.
Gatmaitan, Michelle
Liu, Shanshan
Wang, Yenny
Nyangau, Edna
Colangelo, Marc
Angel, Thomas E.
Beysen, Carine
Cui, Jeffrey
Hernandez, Carolyn
Lazaro, Len
Brenner, David A.
Turner, Scott M.
Hellerstein, Marc K.
Loomba, Rohit
author_facet Decaris, Martin L.
Li, Kelvin W.
Emson, Claire L.
Gatmaitan, Michelle
Liu, Shanshan
Wang, Yenny
Nyangau, Edna
Colangelo, Marc
Angel, Thomas E.
Beysen, Carine
Cui, Jeffrey
Hernandez, Carolyn
Lazaro, Len
Brenner, David A.
Turner, Scott M.
Hellerstein, Marc K.
Loomba, Rohit
author_sort Decaris, Martin L.
collection PubMed
description Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to quantify hepatic fibrogenesis flux rates both directly in liver tissue and noninvasively in blood. Twenty‐one patients with suspected NAFLD ingested heavy water ((2)H(2)O, 50‐mL aliquots) two to three times daily for 3‐5 weeks prior to a clinically indicated liver biopsy. Liver collagen fractional synthesis rate (FSR) and plasma lumican FSR were measured based on (2)H labeling using tandem mass spectrometry. Patients were classified by histology for fibrosis stage (F0‐F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis (NASH). Magnetic resonance elastography measurements of liver stiffness were also performed. Hepatic collagen FSR in NAFLD increased with advancing disease stage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibrosis score and liver stiffness) and correlated with hemoglobin A1C. In addition, plasma lumican FSR demonstrated a significant correlation with hepatic collagen FSR. Conclusion: Using a well‐characterized cohort of patients with biopsy‐proven NAFLD, this study demonstrates that hepatic scar in NASH is actively remodeled even in advanced fibrosis, a disease that is generally regarded as static and slowly progressive. Moreover, hepatic collagen FSR correlates with established risks for fibrotic disease progression in NASH, and plasma lumican FSR correlates with hepatic collagen FSR, suggesting applications as direct or surrogate markers, respectively, of hepatic fibrogenesis in humans. (Hepatology 2017;65:78‐88).
format Online
Article
Text
id pubmed-5516243
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55162432017-08-02 Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood Decaris, Martin L. Li, Kelvin W. Emson, Claire L. Gatmaitan, Michelle Liu, Shanshan Wang, Yenny Nyangau, Edna Colangelo, Marc Angel, Thomas E. Beysen, Carine Cui, Jeffrey Hernandez, Carolyn Lazaro, Len Brenner, David A. Turner, Scott M. Hellerstein, Marc K. Loomba, Rohit Hepatology Steatohepatitis/Metabolic Liver Disease Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to quantify hepatic fibrogenesis flux rates both directly in liver tissue and noninvasively in blood. Twenty‐one patients with suspected NAFLD ingested heavy water ((2)H(2)O, 50‐mL aliquots) two to three times daily for 3‐5 weeks prior to a clinically indicated liver biopsy. Liver collagen fractional synthesis rate (FSR) and plasma lumican FSR were measured based on (2)H labeling using tandem mass spectrometry. Patients were classified by histology for fibrosis stage (F0‐F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis (NASH). Magnetic resonance elastography measurements of liver stiffness were also performed. Hepatic collagen FSR in NAFLD increased with advancing disease stage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibrosis score and liver stiffness) and correlated with hemoglobin A1C. In addition, plasma lumican FSR demonstrated a significant correlation with hepatic collagen FSR. Conclusion: Using a well‐characterized cohort of patients with biopsy‐proven NAFLD, this study demonstrates that hepatic scar in NASH is actively remodeled even in advanced fibrosis, a disease that is generally regarded as static and slowly progressive. Moreover, hepatic collagen FSR correlates with established risks for fibrotic disease progression in NASH, and plasma lumican FSR correlates with hepatic collagen FSR, suggesting applications as direct or surrogate markers, respectively, of hepatic fibrogenesis in humans. (Hepatology 2017;65:78‐88). John Wiley and Sons Inc. 2016-11-15 2017-01 /pmc/articles/PMC5516243/ /pubmed/27706836 http://dx.doi.org/10.1002/hep.28860 Text en © 2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Steatohepatitis/Metabolic Liver Disease
Decaris, Martin L.
Li, Kelvin W.
Emson, Claire L.
Gatmaitan, Michelle
Liu, Shanshan
Wang, Yenny
Nyangau, Edna
Colangelo, Marc
Angel, Thomas E.
Beysen, Carine
Cui, Jeffrey
Hernandez, Carolyn
Lazaro, Len
Brenner, David A.
Turner, Scott M.
Hellerstein, Marc K.
Loomba, Rohit
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
title Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
title_full Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
title_fullStr Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
title_full_unstemmed Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
title_short Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
title_sort identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
topic Steatohepatitis/Metabolic Liver Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516243/
https://www.ncbi.nlm.nih.gov/pubmed/27706836
http://dx.doi.org/10.1002/hep.28860
work_keys_str_mv AT decarismartinl identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT likelvinw identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT emsonclairel identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT gatmaitanmichelle identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT liushanshan identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT wangyenny identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT nyangauedna identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT colangelomarc identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT angelthomase identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT beysencarine identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT cuijeffrey identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT hernandezcarolyn identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT lazarolen identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT brennerdavida identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT turnerscottm identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT hellersteinmarck identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood
AT loombarohit identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood